Critical Diagnostics Strengthens Leadership Team
Veteran Industry Executive Named President

NEW YORK, NY, August 11, 2005 - Critical Diagnostics, an early-stage healthcare company dedicated to the development of an important new category of diagnostic and prognostic markers that are useful both for the early detection and guiding therapy of both myocardial infarction (heart attack) and heart failure, announced that Dr. James Snider has joined the organization as President.

Prior to joining Critical Diagnostics, Dr. Snider spent over three years as the Executive Vice President of Business & Operations for IntelligentMD ("IMD"), an early-stage medical device company that focuses on the essential elements of disease diagnostics and therapeutic intervention. While at IMD he guided the company through three rounds of fundraising, staffing and resourcing for two product development projects and several business development deals. Prior to joining IMD, Dr. Snider spent eight years in a series of marketing and product development positions at Applied Biosystems (ABI).

Before his tenure at ABI, Dr. Snider was a Senior Scientist at Biotech Research Laboratories, a contracts and service research company specializing in retroviral technologies. Dr. Snider performed his post-doctoral research as a fellow in the Biological Response Modifiers Program at the Frederick Cancer Research & Development Center of the National Cancer Institute. He holds a BS in chemistry from Grand Valley State University, a Ph.D. in chemistry from the University of South Carolina and an MBA in technology management from the University of Phoenix.

For More Information
For more information, please email jsnider@criticaldiagnostics.com